Genentech, Inc.
1 DNA Way
South San Francisco
California
94080-4990
United States
Tel: 650-225-1000
Fax: 650-225-6000
Website: http://www.gene.com/
About Genentech, Inc.
Considered the founder of the industry, Genentech, now a member of the Roche Group, has been delivering on the promise of biotechnology for over 40 years. Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. We are among the world's leading biotech companies, with multiple products on the market and a promising development pipeline. Please take this opportunity to learn about Genentech where we believe that our employees are our most important asset & are dedicated to remaining a great place to work.
Connect with us!
Being a scientist at Genentech means being a drug discoverer. Mike Varney, head of Genentech Research and Early Development, explains how this culture of innovation is helping to solve some of the hardest biomedical problems of our time.
1275 articles with Genentech, Inc.
-
BioSpace, the leader in life sciences news and careers, today announced that Genentech, Pfizer, Merck, Amgen and Novartis landed in the top five spots of their latest Ideal Employer report.
-
Researchers from Genentech and its parent company Roche have developed what is being called the first “deep learning model” that can predict which patients with diabetic retinopathy will progress the fastest.
-
50 million people worldwide live with symptomatic Alzheimer's, which has no cure. In honor of September 21st being World Alzheimer's Day, we evaluated the current therapies, drugs in the pipeline and disease outlook.
-
FDA Grants Breakthrough Therapy Designation for Genentech’s Gazyva (Obinutuzumab) in Lupus Nephritis
9/18/2019
Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to Gazyva® for adults with lupus nephritis.
-
A stigma remains around lung cancer and many people still regard the disease as something of a self-inflicted ailment. But that stigma is waning, new research conducted by the Inova Schar Cancer Institute and Genentech shows.
-
Clinical Catch-Up: September 9-13
9/16/2019
Last week was a busy one for clinical trial results, particularly with the European Committee for Treatment and Research in Multiple Sclerosis 2019 Congress going on. Here’s a look at some of the top clinical trial stories. -
Positive Results Announced From Phase 3 Trial Evaluating Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Using Halozyme's Enhanze® Drug Delivery Technology
9/13/2019
Halozyme Therapeutics, Inc. announced that the global phase III FeDeriCa study conducted by Genentech, a member of the Roche Group, met its primary endpoint.
-
Genentech’s Fixed Dose Subcutaneous Combination of Perjeta and Herceptin Showed Non-Inferiority When Compared to Intravenous Formulations for People With HER2-Positive Breast Cancer
9/13/2019
Genentech, a member of the Roche Group, announced the Phase III FeDeriCa study met its primary endpoint.
-
Genentech Presents New Six-year Ocrevus (Ocrelizumab) Data Which Showed That Earlier Initiation and Continuation of Treatment Reduced Disability Progression in Multiple Sclerosis
9/13/2019
Genentech, a member of the Roche Group, announced longer-term data from the Phase III open-label extension studies of OPERA I, OPERA II and ORATORIO showed that patients who were treated with Ocrevus® continuously for six years or more had reduced risk of disability progression in relapsing MS and primary progressive MS.
-
Genentech’s Tecentriq (Atezolizumab) as a First-Line Monotherapy Helped Certain People With Advanced Non-Small Cell Lung Cancer Live Longer Compared With Chemotherapy
9/12/2019
Data will be shared with health authorities globally, including the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA)
-
Genentech’s Satralizumab Significantly Reduced Relapse Risk in Second Positive Phase III Study for Neuromyelitis Optica Spectrum Disorder
9/12/2019
Genentech, a member of the Roche Group, presented full pivotal Phase III study results for satralizumab as a monotherapy for neuromyelitis optica spectrum disorder, a rare, debilitating central nervous system disease.
-
The company presented the data at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
-
Genentech Presents New Ocrevus (Ocrelizumab) Biomarker Data That Increase Understanding of Disease Progression in Multiple Sclerosis at ECTRIMS
9/10/2019
Genentech, a member of the Roche Group, announced new data from Ocrevus® trials in relapsing and primary progressive multiple sclerosis.
-
Clinical Catch-Up: September 2-8
9/9/2019
Last week was a busy week for clinical trial results. Here’s a look at some of the top stories and reporting. -
Nearly one year after charges were filed against former Genentech employees accused of stealing trade secrets to benefit JHL Biotech, the two companies have come to an agreement over the ill-gotten intellectual property – destruction.
-
Abionic Signs Agreement to Optimize Asthma Management in the U.S. through Innovative Rapid Point-of-Care Tests
9/5/2019
Abionic SA and Genentech announced a strategic agreement to develop and provide an In Vitro Diagnostic (IVD) Asthma Test Panel using Abionic’s POC abioSCOPE® platform in the United States.
-
Genentech to Present Pivotal Data for Satralizumab in Neuromyelitis Optica Spectrum Disorder and Six-year Ocrevus (Ocrelizumab) Data in Multiple Sclerosis at ECTRIMS
9/4/2019
Genentech, a member of the Roche Group, announced that new data across its neuroscience portfolio will be presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis from September 11-13 in Stockholm.
-
Genentech said Phase III data from the BLOCKSTONE study showed that an individual treated with Xofluza after being exposed to the flu by an infected household member, reduced the risk of developing the flu by 86% compared to placebo.
-
Positive Phase III Results Show Xofluza (Baloxavir Marboxil) Reduces Risk of Developing the Flu After Contact With an Infected Person by 86 Percent
9/2/2019
Genentech, a member of the Roche Group, announced that the Phase III BLOCKSTONE study showed preventive treatment with Xofluza™ after exposure to an infected household member significantly reduced the risk of people developing the flu by 86 percent versus placebo.
-
Genentech Presents Positive Phase III Study Results for One-dose Xofluza (Baloxavir Marboxil) in Children With the Flu
9/2/2019
Genentech, a member of the Roche Group, announced that the Phase III MINISTONE-2 study showed that one-dose Xofluza™ was a well-tolerated and effective potential treatment for the flu in otherwise healthy children aged one to less than 12 years old.